2 results about "Non responders" patented technology

The present invention relates to a prebiotic composition for use in a method for maintaining or improving the health of a subject in need thereof, comprising at least one inulin-type fructan (ITF) and at least one human milk oligosaccharide (HMO), wherein the subject in need thereof is an HMO non-responder; a food, a dietary supplement or a drink comprising a prebiotic composition for use in a method for maintaining or improving the health of a subject in need thereof, wherein the subject in need thereof is an HMO non-responder; and an inulin-type fructan (ITF) for use in a method for maintaining or improving the health of a subject in need thereof by administering a prebiotic composition comprising at least one human milk oligosaccharide (HMO), wherein the subject in need thereof is an HMO non-responder.The present invention also relates to the use of said prebiotic composition as a dietary supplement, food or drink for prebiotic non-responders. The present invention also relates to a prebiotic composition comprising at least one inulin-type fructan (ITF) and at least one human milk oligosaccharide (HMO) for use in a method for the treatment of a mood disorder, preferably depression or anxiety, wherein a subject in need thereof is an HMO non-responder.

The invention generally relates to the field of diagnostics and prognostics. In particular, the invention relates to a method for determining the responsiveness of a chronic hepatitis B (CHB) patient to IFN-alpha treatment. In an aspect of the invention, there is provided a method for determining the responsiveness of a chronic hepatitis B (CHB) patient to IFN-alpha treatment, comprising: (a) measuring an expression level of at least one biomarker of a prognostic biomarker panel selected from the group consisting of NQO2, MBL2, IGKV3D-20, PKHD1L1, PGLYRP1, KHSRP, LCN2, and ROBO1 in a biological sample obtained from the patient, and (b) comparing the expression level of the at least one biomarker to corresponding expression level of a known non-responder, wherein an expression level higher than the corresponding expression level is indicative of a likelihood of a positive response to IFN-alpha treatment.